Beate Appenrodt

Summary

Affiliation: University of Bonn
Country: Germany

Publications

  1. ncbi A patient with portal hypertension and blindness after transjugular intrahepatic portosystemic shunt
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 18:447-9. 2006
  2. ncbi [Antibiotic therapy and prophylaxis in liver cirrhosis and infection]
    B Appenrodt
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Bonn
    Dtsch Med Wochenschr 132:623-6. 2007
  3. doi Is detection of bacterial DNA in ascitic fluid of clinical relevance?
    Beate Appenrodt
    Departments of aInternal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 22:1487-94. 2010
  4. doi Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Liver Int 28:1019-25. 2008
  5. doi Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 21:1428-32. 2009
  6. doi Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis
    Beate Appenrodt
    Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
    Hepatology 51:1327-33. 2010
  7. doi [Complications of liver cirrhosis, medical management]
    Frank Grunhage
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Rheinische Friedrich Wilhelms Universitat, Bonn
    Med Klin (Munich) 103:482-90. 2008
  8. ncbi Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study
    Michael Schepke
    Department of Internal Medicine I, General Internal Medicine, University of Bonn, Germany
    Liver Int 26:834-9. 2006
  9. pmc The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis
    Tilman Sauerbruch
    Department of Internal Medicine I at the University Hospital of Bonn, Bonn, Germany
    Dtsch Arztebl Int 110:126-32, I. 2013
  10. doi Coexisting gastric varices should not preclude prophylactic ligation of large esophageal varices in cirrhosis
    Michael Schepke
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Digestion 80:165-9. 2009

Detail Information

Publications17

  1. ncbi A patient with portal hypertension and blindness after transjugular intrahepatic portosystemic shunt
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 18:447-9. 2006
    ..The present case report shows a very rare but important complication after TIPS implantation. To avoid this complication it is recommended to perform echocardiography before all TIPS placements...
  2. ncbi [Antibiotic therapy and prophylaxis in liver cirrhosis and infection]
    B Appenrodt
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Bonn
    Dtsch Med Wochenschr 132:623-6. 2007
  3. doi Is detection of bacterial DNA in ascitic fluid of clinical relevance?
    Beate Appenrodt
    Departments of aInternal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 22:1487-94. 2010
    ..However, the clinical relevance of this finding is ill-defined especially compared with the standard diagnostics for detection of spontaneous bacterial peritonitis (SBP). Furthermore, other DNA tests have not been sufficiently evaluated...
  4. doi Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Liver Int 28:1019-25. 2008
    ..Vasoconstrictors, e.g. terlipressin, may also prevent PICD. The aim was to compare the less expensive vasoconstrictor midodrine, an alpha-adrenoceptor agonist, with albumin in preventing PICD...
  5. doi Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 21:1428-32. 2009
    ..Therefore, it is important to define parameters that predict an improved outcome in respect to kidney function and survival...
  6. doi Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis
    Beate Appenrodt
    Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
    Hepatology 51:1327-33. 2010
    ..These findings might serve to identify patients with cirrhotic ascites eligible for preemptive antibiotic treatment...
  7. doi [Complications of liver cirrhosis, medical management]
    Frank Grunhage
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Rheinische Friedrich Wilhelms Universitat, Bonn
    Med Klin (Munich) 103:482-90. 2008
    ..At the same time, treatment of the underlying disease, the identification and treatment of triggering factors, and the possibility of liver transplantation should be kept in mind...
  8. ncbi Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study
    Michael Schepke
    Department of Internal Medicine I, General Internal Medicine, University of Bonn, Germany
    Liver Int 26:834-9. 2006
    ..The current study prospectively evaluated the incidence and the prognostic relevance of different etiologies of kidney failure in cirrhotic patients...
  9. pmc The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis
    Tilman Sauerbruch
    Department of Internal Medicine I at the University Hospital of Bonn, Bonn, Germany
    Dtsch Arztebl Int 110:126-32, I. 2013
    ..The main complications of cirrhosis arise in turn: These include bleeding from collateral veins, ascites, hepatocellular carcinoma, encephalopathy, and infection leading to organ failure...
  10. doi Coexisting gastric varices should not preclude prophylactic ligation of large esophageal varices in cirrhosis
    Michael Schepke
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Digestion 80:165-9. 2009
    ..Coexisting gastric varices at baseline or the risk of their formation during treatment could alter the approach for primary bleeding prophylaxis in patients with large esophageal varices...
  11. doi Atypical Ormond's disease associated with bile duct stricture mimicking cholangiocarcinoma
    Michael Quante
    Department of Medicine I, University Hospital Bonn, Germany
    Scand J Gastroenterol 44:116-20. 2009
    ..Treatment with tamoxifen was initiated. To the best of our knowledge, only a few cases of intraperitoneal fibroses mimicking cholangiocarcinoma followed by the typical symptoms of retroperitoneal Ormond's disease have been reported...
  12. doi Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care
    Christian Rabe
    Medical ICU, Department of Internal Medicine I, University of Bonn, D 53105 Bonn, Germany
    J Crit Care 25:230-5. 2010
    ..The aim of this study was to characterize patients and report outcome of diffuse alveolar hemorrhage (DAH) requiring intensive care unit support...
  13. doi Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt
    Jonel Trebicka
    Department of Internal Medicine I, University of Bonn, Germany
    Eur J Gastroenterol Hepatol 23:1218-25. 2011
    ..However, the hepatic elimination of endotoxin in cirrhotic patients with severe portal hypertension, in the absence of acute complications, has not been investigated so far...
  14. ncbi [Medical therapy of complications in liver cirrhosis]
    F Grunhage
    Medizinische Klinik und Poliklinik I, Universitatsklinikum, Rheinische Friedrich Wilhelms Universitat, Sigmund Freud Strasse 25, Bonn, Germany
    Internist (Berl) 48:1349-57. 2007
    ..At the same time treatment of the underlying disease, the identification and treatment of triggering factors and the possibility of liver transplantation should be kept in mind...
  15. ncbi [Gastrointestinal bleeding in portal hypertension in liver cirrhosis]
    E Biecker
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn
    Z Gastroenterol 43:35-46. 2005
    ..Bleeding from ectopic varices and bleeding from hypertensive gastropathy should be treated individually either by endoscopy, TIPS or drug therapy...
  16. pmc A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
    ..The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS...
  17. ncbi Insufficient sensitivity of reagent strips for spontaneous bacterial peritonitis
    Veit Gulberg
    Hepatology 46:1669; author reply 1669-70. 2007